STAMFORD, Conn., Feb. 15 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. announced today it will be co-sponsoring the Second International Symposium on Regional Cancer Therapies on February 24-26, 2007 in San Juan, Puerto Rico. The Symposium is being sponsored by the David C. Koch Regional Perfusion Cancer Therapy Center of the University of Pittsburgh Cancer Centers.
During the Symposium, the National Cancer Institute ("NCI") is scheduled to present select data from Delcath Systems' ongoing Phase II multi-histology trial of treating unresectable primary and metastatic cancers of the liver using the Delcath System with melphalan.
Richard Taney, CEO of Delcath Systems, said, "We are excited to be co-sponsoring this important event. The Delcath System is a unique and powerful delivery system with multiple regional cancer therapy applications. We are eager to show our support of the work being done in regional perfusion therapy and to raise awareness of the Delcath System with members of the medical community that share our dedication to the fight against cancer."
The Second International Symposium will serve as a comprehensive forum to promote the research, development and application of the most recent advances in regional therapies in surgical oncology, while supporting the exchange of information among healthcare professionals. The course co-directors at the event include Dr. H. Richard Alexander, Professor of Surgery, University of Maryland Medical Center, Dr. David L. Bartlett, Professor of Surgery, University of Pittsburgh School of Medicine, and Dr. Robert P. Edwards, Visiting Professor Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine.
In attendance at the symposium will be physicians and nurses practicing in the areas of medical, surgical, thoracic and gynecologic oncology and gastroenterology and researchers involved in the field of hyperthermia and regionally applied biologic therapies. For more information on the symposium please visit www.regionaltherapies.com.
About Delcath Systems, Inc.
Delcath Systems is a developer of percutaneous perfusion technology for organ or region-specific delivery of therapeutic agents. The Company's intellectual property portfolio currently consists of 12 patents on a worldwide basis, including the United States, Europe, Asia and Canada. For more information, please visit the Company's website, www.delcath.com.
This release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.
Company Contact: Investor Contacts: Delcath Systems, Inc. Todd Fromer / Garth Russell Richard Taney KCSA Worldwide 203-323-8668 (212) 896-1215 / (212) 896-1250 www.delcath.comtfromer@kcsa.com / grussell@kcsa.com Media Contact: Lewis Goldberg KCSA Worldwide (212) 896-1216 lgoldberg@kcsa.com
Delcath Systems, Inc.CONTACT: Richard Taney of Delcath Systems, Inc., +1-203-323-8668; orInvestor Contacts, Todd Fromer, +1-212-896-1215, tfromer@kcsa.com, or GarthRussell, +1-212-896-1250, grussell@kcsa.com, or Media Contact, LewisGoldberg, +1-212-896-1216, lgoldberg@kcsa.com, all of KCSA Worldwide forDelcath Systems, Inc.
